MEtabolic Therapy with Trimetazidine in Acute heart failure: an open pilot randomized trial (The METTA – PRAGUE 10 Trial) - METTA - PRAGUE 10

Charles University in Prague, Third Faculty of Medicine0 个研究点目标入组 100 人开始时间: 2007年7月12日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.Dyspnea at rest due to acute heart failure (defined as a presence of at least one of the following: S3 gallop OR pulmonary rales OR X-ray prove of pulmonary congestions OR PCW pressure > 25 mmHg).
•2.Decreased oxygen saturation (value obtained from pulse oxymetry) within one hour of admission to ICU.
•3.Signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Age less than 18 years.
•2.Acute persistent ST-elevation on ECG at admission.
•3.Progressive shock (defined as spontaneous systolic blood pressure < 90 mmHg OR systolic blood pressure < 100 mmHg despite dopamin or dobutamin therapy up to 8 µg/kg/min OR any hypotension requiring noradrenalin or adrenalin administration).
•4.Patient already on metabolic-modulation therapy.
•5.History of allergy to trimetazidine or any additives present in the drug.
•6.Inability to ingest oral medication.
•7.Unwillingness to be followed for the duration of the study.
•8.Women of childbearing potential who are pregnant, nursing or not using effective contraception.
•9.Disability of oral drug intake.

发起方

Charles University in Prague, Third Faculty of Medicine